Recruiting
A Study of LY3561774 in Participants With Dyslipidemia.
J3F-MC-EZCA - ClinicalTrials.gov - NCT04644809
This is a 3-part study. In Parts A and B, the main purpose is to evaluate the safety and tolerability of the study drug known as LY3561774 in participants with dyslipidemia (high blood fat levels). How the body processes the study drug and the effect of the study drug on blood fat levels will also be investigated. Part C will mainly evaluate the safety and tolerability of LY3561774 as well as how the body processes the study drug in Japanese participants.
How long will I be in the trial?
The study may last up 52, 56 and 28 weeks for each participant in Parts A, B and C, respectively. There are up to 22, 26 and 16 visits in Parts A, B and C, respectively.
Recruiting
A Study of LY3561774 in Participants With Dyslipidemia.
J3F-MC-EZCA - ClinicalTrials.gov - NCT04644809
This is a 3-part study. In Parts A and B, the main purpose is to evaluate the safety and tolerability of the study drug known as LY3561774 in participants with dyslipidemia (high blood fat levels). How the body processes the study drug and the effect of the study drug on blood fat levels will also be investigated. Part C will mainly evaluate the safety and tolerability of LY3561774 as well as how the body processes the study drug in Japanese participants.
How long will I be in the trial?
The study may last up 52, 56 and 28 weeks for each participant in Parts A, B and C, respectively. There are up to 22, 26 and 16 visits in Parts A, B and C, respectively.
Key Requirements
Age :
18-65
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18-65
Sex
All
Participants must
Participants must have high blood fat levels for Part A and B
Participants must be first generation Japanese origin for Part C
Participants must have a body mass index (BMI) of 18.5 to 40.0 kilograms per square meter (kg/m²)
Male participants must agree to adhere to contraception restrictions and female participants must not be able to get pregnant
Participants must NOT
Participants must not have taken any prescription medications that are for blood fat lowering within the past 2 months (use of statins is allowed if the dose has been stable for 8 weeks)
Participants must not have Type 1 diabetes
Participants must not have currently participated in or completed a clinical trial within the last 30 days
Participants must not be a heavy alcohol drinker or heavy cigarette smoker
Participants must not have donated blood of more than 500 milliliters (mL) in the last 3 months
Trial Summary
Conditions the trial is for
Dyslipidemia
What the trial is testing?
LY3561774
Could I receive a Placebo?
yes
Enrollment Goal
74
Trial Dates
November 2020 - April 2022
Trial Phase
1
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18-65
Sex
All
Participants must
Participants must have high blood fat levels for Part A and B
Participants must be first generation Japanese origin for Part C
Participants must have a body mass index (BMI) of 18.5 to 40.0 kilograms per square meter (kg/m²)
Male participants must agree to adhere to contraception restrictions and female participants must not be able to get pregnant
Participants must NOT
Participants must not have taken any prescription medications that are for blood fat lowering within the past 2 months (use of statins is allowed if the dose has been stable for 8 weeks)
Participants must not have Type 1 diabetes
Participants must not have currently participated in or completed a clinical trial within the last 30 days
Participants must not be a heavy alcohol drinker or heavy cigarette smoker
Participants must not have donated blood of more than 500 milliliters (mL) in the last 3 months
Trial Summary
Conditions the trial is for
Dyslipidemia
What the trial is testing?
LY3561774
Could I receive a Placebo?
yes
Enrollment Goal
74
Trial Dates
November 2020 - April 2022
Trial Phase
1
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Dyslipidemia Resources
